A.R.T. Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

A.R.T. Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-67,767	Closed	-$1.62M	–	1251
2019 Q4	$1.62M	Buy	+67,767	New	+$1.87M	0.08%	376
2019 Q2	–	Sell	-29,667	Closed	-$1.03M	–	1769
2019 Q1	$1.03M	Buy	+29,667	New	+$856K	0.06%	470
2018 Q3	–	Sell	-5,300	Closed	-$200K	–	1850
2018 Q2	$200K	Buy	+5,300	New	+$203K	0.01%	1233
2018 Q1	–	Sell	-11,900	Closed	-$579K	–	1881
2017 Q4	$579K	Sell	11,900 -43,800	-79%	-$2.22M	0.03%	835
2017 Q3	$3.01M	Sell	55,700 -1,800	-3%	-$106K	0.15%	166
2017 Q2	$3.23M	Sell	57,500 -48,200	-46%	-$1.93M	0.17%	134
2017 Q1	$4.14M	Buy	+105,700	New	+$3.37M	0.19%	138
2016 Q2	–	Sell	-35,812	Closed	-$730K	–	1755
2016 Q1	$730K	Buy	+35,812	New	+$1.14M	0.03%	712
2015 Q2	–	Sell	-39,633	Closed	-$1.5M	–	1819
2015 Q1	$1.5M	Buy	+39,633	New	+$1.36M	0.05%	503
2014 Q3	–	Sell	-12,918	Closed	-$376K	–	1619
2014 Q2	$376K	Buy	+12,918	New	+$313K	0.02%	898

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

A.R.T. Advisors's PTLA Position: Q1 2020 in Review

A.R.T. Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 67,767 shares — an estimated $1.62M sold.

A.R.T. Advisors first reported a position in PTLA in Q2 2014 and held it in 10 quarters. The position peaked at $4.14M in Q1 2017. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

A.R.T. Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 67,767 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.62M.
A.R.T. Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q2 2014 and held it in 10 quarters.
A.R.T. Advisors's Portola Pharmaceuticals, Inc. position peaked at $4.14M in Q1 2017.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.